Billions Saved Because FDA Didn ' t Rush Approval of Alzheimer ' s Drug Billions Saved Because FDA Didn ' t Rush Approval of Alzheimer ' s Drug

The U.S. Food and Drug Administration ' s decision not to rush approval for Eli Lilly ' s experimental Alzheimer ' s treatment solanezumab - a drug that turned out to be ineffective - may have saved American taxpayers as much as $100 billion over the past four years, an analysis concludes.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news